<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00187226</url>
  </required_header>
  <id_info>
    <org_study_id>RT1</org_study_id>
    <nct_id>NCT00187226</nct_id>
  </id_info>
  <brief_title>A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects</brief_title>
  <official_title>A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to determine if treating a limited volume of normal tissue
      surrounding the tumor or tumor bed using conformal radiation therapy would achieve similar
      rates of disease control compared to standard radiation therapy. The study was also conducted
      to examine the effect of irradiation on neurological, endocrine and cognitive function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation therapy is commonly used to treat a variety of brain tumors in children including
      ependymoma, craniopharyngioma and low- and high-grade glioma. The ability of the therapy to
      control brain tumors in children is known to depend on the tumor type, extent of resection
      and other clinical factors. Children who received radiation therapy on this study were
      evaluated for treatment failure at 12 months. In addition to the primary objective, the study
      was designed to explore the association between radiation dose and volume and a variety of
      neurological, endocrine and cognitive deficits up to 5 years after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Tumor Control</measure>
    <time_frame>12 months after the enrollment of the last therapeutic patient</time_frame>
    <description>Local tumor control was determined by Magnetic Resonance Imaging (MRI) of the brain and spine performed after radiation therapy. Imaging studies were performed every 3-4 months during the first three years and then every 6 months through five years. Imaging studies demonstrating tumor progression were electronically registered to the imaging data used to plan therapy. Local failure included tumor progression within the volume that received the prescribed dose of irradiation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Central Nervous System Tumors</condition>
  <condition>Brain Tumors</condition>
  <arm_group>
    <arm_group_label>Stratum 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ependymoma, craniopharyngioma, low-grade glioma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>High-grade glioma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.</description>
    <arm_group_label>Stratum 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.</description>
    <arm_group_label>Stratum 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at time of irradiation is greater than or equal to 8 months and less than or equal
             to 25 years

          -  Histologically diagnosed craniopharyngioma, ependymoma, low-grade astrocytoma or
             high-grade glioma and radiographically diagnosed selected patients with
             craniopharyngioma and low-grade glioma.

          -  Adequate performance status, participant has an ECOG (Performance Status Score) of
             0-2(0=Normal Activity; 1=Symptoms but Ambulatory; 2=Bedridden &lt;50% of time)

          -  Histologic type that requires only focal irradiation.

          -  No prior fractionated external beam irradiation

          -  Informed consent signed by patient, parent, or guardian.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E. Merchant, D.O., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>May 4, 2012</results_first_submitted>
  <results_first_submitted_qc>August 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2012</results_first_posted>
  <last_update_submitted>August 17, 2012</last_update_submitted>
  <last_update_submitted_qc>August 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain neoplasm</keyword>
  <keyword>Brain cancer</keyword>
  <keyword>Neoplasm intracranial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>202 patients were enrolled between July 11, 1997 and January 14, 2003 for the therapeutic phase of the trial. Among those patients, 167 were treated with a 1cm clinical target volume (CTV) margin and 35 were treated with a 2cm CTV margin. Local tumor progression was determined by MR imaging.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1cm Clinical Target Volume Margin - Ependymoma</title>
          <description>Patients with Ependymoma in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="P2">
          <title>1cm Clinical Target Volume Margin - Low-grade Glioma</title>
          <description>Patients with Low-grade Glioma in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="P3">
          <title>1cm Clinical Target Volume Margin - Craniopharyngioma</title>
          <description>Patients with Craniopharyngioma in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="P4">
          <title>1cm Clinical Target Volume Margin - Other</title>
          <description>Remaining patients in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="P5">
          <title>2cm Clinical Target Volume Margin - High-grade Glioma</title>
          <description>Patients with High-grade glioma in the 2cm clinical target volume margin group.</description>
        </group>
        <group group_id="P6">
          <title>2cm Clinical Target Volume Margin - Low-grade Glioma</title>
          <description>Patients with Low-grade Glioma in the 2cm clinical target volume margin group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1cm Clinical Target Volume Margin - Ependymoma</title>
          <description>Patients with Ependymoma in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="B2">
          <title>1cm Clinical Target Volume Margin - Low-grade Glioma</title>
          <description>Patients with Low-grade Glioma in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="B3">
          <title>1cm Clinical Target Volume Margin - Craniopharyngioma</title>
          <description>Patients with Craniopharyngioma in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="B4">
          <title>1cm Clinical Target Volume Margin - Other</title>
          <description>Remaining patients in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="B5">
          <title>2cm Clinical Target Volume Margin - High-grade Glioma</title>
          <description>Patients with High-grade glioma in the 2cm clinical target volume margin group.</description>
        </group>
        <group group_id="B6">
          <title>2cm Clinical Target Volume Margin - Low-grade Glioma</title>
          <description>Patients with Low-grade Glioma in the 2cm clinical target volume margin group.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="34"/>
            <count group_id="B6" value="1"/>
            <count group_id="B7" value="202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local Tumor Control</title>
        <description>Local tumor control was determined by Magnetic Resonance Imaging (MRI) of the brain and spine performed after radiation therapy. Imaging studies were performed every 3-4 months during the first three years and then every 6 months through five years. Imaging studies demonstrating tumor progression were electronically registered to the imaging data used to plan therapy. Local failure included tumor progression within the volume that received the prescribed dose of irradiation.</description>
        <time_frame>12 months after the enrollment of the last therapeutic patient</time_frame>
        <population>Patients with Ependymoma, Craniopharyngioma, Low-grade Glioma, and High-grade Glioma were analyzed by diagnosis.</population>
        <group_list>
          <group group_id="O1">
            <title>1cm Clinical Target Volume Margin - Ependymoma</title>
            <description>Patients with Ependymoma in the 1cm clinical target volume margin group.</description>
          </group>
          <group group_id="O2">
            <title>1cm Clinical Target Volume Margin - Low-grade Glioma</title>
            <description>Patients with Low-grade Glioma in the 1cm clinical target volume margin group.</description>
          </group>
          <group group_id="O3">
            <title>1cm Clinical Target Volume Margin - Craniopharyngioma</title>
            <description>Patients with Craniopharyngioma in the 1cm clinical target volume margin group.</description>
          </group>
          <group group_id="O4">
            <title>1cm Clinical Target Volume Margin - Other</title>
            <description>Remaining patients in the 1cm clinical target volume margin group.</description>
          </group>
          <group group_id="O5">
            <title>2cm Clinical Target Volume Margin - High-grade Glioma</title>
            <description>Patients with High-grade glioma in the 2cm clinical target volume margin group.</description>
          </group>
          <group group_id="O6">
            <title>2cm Clinical Target Volume Margin - Low-grade Glioma</title>
            <description>Patients with Low-grade Glioma in the 2cm clinical target volume margin group.</description>
          </group>
        </group_list>
        <measure>
          <title>Local Tumor Control</title>
          <description>Local tumor control was determined by Magnetic Resonance Imaging (MRI) of the brain and spine performed after radiation therapy. Imaging studies were performed every 3-4 months during the first three years and then every 6 months through five years. Imaging studies demonstrating tumor progression were electronically registered to the imaging data used to plan therapy. Local failure included tumor progression within the volume that received the prescribed dose of irradiation.</description>
          <population>Patients with Ependymoma, Craniopharyngioma, Low-grade Glioma, and High-grade Glioma were analyzed by diagnosis.</population>
          <units>Proportion of patients</units>
          <param>Log Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.966" lower_limit="0.904" upper_limit="0.993"/>
                    <measurement group_id="O2" value="0.959" lower_limit="0.860" upper_limit="0.995"/>
                    <measurement group_id="O3" value="1.000" lower_limit="0.877" upper_limit="1.000"/>
                    <measurement group_id="O4" value="1.000" lower_limit="1.000" upper_limit="1.000"/>
                    <measurement group_id="O5" value="0.618" lower_limit="0.436" upper_limit="0.778"/>
                    <measurement group_id="O6" value="1.000" lower_limit="1.000" upper_limit="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients enrolled on this study included 202 patients who were enrolled between July 11, 1997 and January 14, 2003. Patients are followed 30 days post off-study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1cm Clinical Target Volume Margin - Ependymoma</title>
          <description>Patients with Ependymoma in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="E2">
          <title>1cm Clinical Target Volume Margin - Low-grade Glioma</title>
          <description>Patients with Low-grade Glioma in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="E3">
          <title>1cm Clinical Target Volume Margin - Craniopharyngioma</title>
          <description>Patients with Craniopharyngioma in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="E4">
          <title>1cm Clinical Target Volume Margin - Other</title>
          <description>Remaining patients in the 1cm clinical target volume margin group.</description>
        </group>
        <group group_id="E5">
          <title>2cm Clinical Target Volume Margin - High-grade Glioma</title>
          <description>Patients with High-grade glioma in the 2cm clinical target volume margin group.</description>
        </group>
        <group group_id="E6">
          <title>2cm Clinical Target Volume Margin - Low-grade Glioma</title>
          <description>Patients with Low-grade Glioma in the 2cm clinical target volume margin group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuromotor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas E. Merchant, DO, PhD</name_or_title>
      <organization>St. Jude Children's Research Hospital</organization>
      <phone>901-595-3604</phone>
      <email>thomas.merchant@stjude.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

